Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novartis discloses novel prodrugs of SGLT1/2 inhibitors

Nov. 14, 2012

NDA for nonhormonal therapy for menopausal vasomotor symptoms accepted for review by FDA

Nov. 14, 2012

Edison Pharmaceuticals commences phase IIb trial of EPI-743 in children with Leigh syndrome

Nov. 14, 2012

Preliminary clinical results presented for FG-4592 in hemodialysis patients

Nov. 14, 2012

FDA advisory committee votes on insulin degludec NDAs

Nov. 12, 2012

Novel RNAi therapeutic significantly reduces triglycerides and LDL

Nov. 12, 2012

Successful results reported for phase IIb trial of bremelanotide

Nov. 12, 2012

Merck & Co. prepares novel agents for diabetes and obesity

Nov. 9, 2012

Signifor recommended by FDA advisory committee for Cushing's disease

Nov. 9, 2012

Aspireo Pharmaceuticals begins phase IIa trial of Somatoprim

Nov. 8, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...